Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pharyngitis streptococcal11.02.06.002; 22.07.04.001--Not Available
Plasma cell myeloma16.23.02.004; 01.14.02.004--Not Available
Platelet count abnormal13.01.04.0050.000799%Not Available
Platelet count decreased13.01.04.0010.018915%
Pleural effusion22.05.02.0020.009058%
Pleurisy22.05.01.0010.000799%Not Available
Pneumonia22.07.01.003; 11.01.09.0030.017236%Not Available
Pneumonia aspiration22.01.01.005--Not Available
Pneumonia klebsiella22.07.06.001; 11.02.03.0010.000139%Not Available
Pneumonitis22.01.01.0060.002931%
Pneumothorax22.05.02.003--
Pollakiuria20.02.02.007--
Polycythaemia01.07.01.0010.000799%Not Available
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.007--
Proctalgia07.03.02.0010.001066%
Productive cough22.02.03.005--
Progressive multifocal leukoencephalopathy17.16.02.002; 11.05.05.0010.000278%Not Available
Prostatic disorder21.04.01.0010.000533%Not Available
Prostatitis21.09.01.0010.000799%Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Pseudomembranous colitis11.02.02.002; 07.19.01.0030.000799%Not Available
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000278%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.006--
Pulmonary haemorrhage22.02.04.003; 24.07.01.0160.000208%
Pulmonary hypertension24.08.03.002; 22.06.01.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000799%
Pyoderma gangrenosum23.07.03.001; 16.32.03.005; 10.04.02.0090.003996%Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 24 Pages